Anzeige
Mehr »
Freitag, 13.02.2026 - Börsentäglich über 12.000 News
Die Kommerzialisierung der räumlichen Intelligenz in Billionen-Märkten beginnt jetzt
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
483 Leser
Artikel bewerten:
(2)

Firmenich Appoints Dr. Sarah Reisinger as Chief Research Officer

GENEVA, May 20, 2021 /PRNewswire/ -- Firmenich, the world's largest privately owned fragrance and taste company, appoints Sarah Reisinger as Chief Research Officer, effective July 1, 2021. She will report to the Group CEO, Gilbert Ghostine, as a member of his executive team after most recently serving as Senior Vice President of Research Operations. Dr. Reisinger will succeed Professor Geneviève Berger, who is staying on as a Strategic Advisor to the CEO, before her retirement from the Group on December 31, 2021.

Sarah Reisinger, new Chief Research Officer, Firmenich

In her new role, Dr. Reisinger will lead Firmenich through new frontiers of scientific excellence, building on the Group's track record of industry-leading innovation.

"Sarah brings a unique blend of world-class experience in management of Research and Development, both in start-up as well as larger organization structures, with a strong background in biotechnology, augmented discovery and open innovation. I am very proud to welcome her to my executive team," said Gilbert Ghostine. "Firmenich is shaping the future of fragrance and taste, and this next-generation appointment demonstrates our continued commitment to our customers, providing cutting-edge technology and sustainable solutions that match the fast-evolving needs of consumers."

"I am excited to have this opportunity to build on our amazing legacy of scientific excellence by leading Research into fast evolving scientific domains and embracing new technology for our changing world," said Dr. Reisinger. "Our team's multidisciplinary and global approach to innovation in perfume, taste and ingredients are immense assets to deliver breakthrough solutions for our clients."

"I wish to warmly thank Professor Berger for successfully building the multidisciplinary strength of our Research & Development and for championing white biotechnology. Under her leadership, we have broadened our scope of research and reinforced our global footprint in science with new R&D centers, targeted acquisitions, and were the first to market with AI-generated solutions in taste and fragrance," said Gilbert Ghostine. "I will continue to count on her recognized world-class expertise in science and business over the coming months."

Dr. Reisinger has an extensive background in biotechnology as well as a strong track record in ingredients and technology development for the consumer goods industry. Prior to joining Firmenich in 2018 as VP Biotechnology and Process Engineering, she held pivotal roles at Ginkgo Bioworks, Intrexon and Amyris, after starting her career in the field of biology and cancer therapeutics. Dr. Reisinger holds a B.S. in Biology from Harvey Mudd College, US, as well as an M.S. in Plant Biology and a Ph.D. in Microbiology from the University of California, Berkeley.

Firmenich's industry-leading commitment to research and development is backed by the annual average investment of 10% of its turnover to drive groundbreaking science. The Group's Research division runs six centers of excellence in Geneva, Switzerland; New York, Princeton, San Diego, USA; Shanghai, China; and Gujarat, India. It also works closely with a network of external partners, including leading academic institutions and cutting-edge start-ups.

About Firmenich
Firmenich, the world's largest privately-owned fragrance and taste company, was founded in Geneva, Switzerland, in 1895, and has been family-owned for 125 years. Firmenich is a leading business-to-business company specialized in the research, creation, manufacture and sale of perfumes, flavors and ingredients. Renowned for its world-class research and creativity, as well as its leadership in sustainability, Firmenich offers its customers superior innovation in formulation, a broad and high-quality palette of ingredients, and proprietary technologies including biotechnology, encapsulation, olfactory science and taste modulation. Firmenich had an annual turnover of 3.9 billion Swiss Francs at end June 2020. More information about Firmenich is available at www.firmenich.com.

Firmenich Logo

Photo - https://mma.prnewswire.com/media/1514424/Sarah_Reisinger.jpg
Logo - https://mma.prnewswire.com/media/798187/Firmenich_Logo.jpg

© 2021 PR Newswire
Favoritenwechsel - diese 5 Werte sollten Anleger im Depot haben!
Das Börsenjahr 2026 ist für viele Anleger ernüchternd gestartet. Tech-Werte straucheln, der Nasdaq 100 tritt auf der Stelle und ausgerechnet alte Favoriten wie Microsoft und SAP rutschen zweistellig ab. KI ist plötzlich kein Rückenwind mehr, sondern ein Belastungsfaktor, weil Investoren beginnen, die finanzielle Nachhaltigkeit zu hinterfragen.

Gleichzeitig vollzieht sich an der Wall Street ein lautloser Favoritenwechsel. Während viele auf Wachstum setzen, feiern Value-Titel mit verlässlichen Cashflows ihr Comeback: Telekommunikation, Industrie, Energie, Pharma – die „Cashmaschinen“ der Realwirtschaft verdrängen hoch bewertete Hoffnungsträger.

In unserem aktuellen Spezialreport stellen wir fünf Aktien vor, die genau in dieses neue Marktbild passen: solide, günstig bewertet und mit attraktiver Dividende. Werte, die nicht nur laufende Erträge liefern, sondern auch bei Marktkorrekturen Sicherheit bieten.

Jetzt den kostenlosen Report sichern – bevor der Value-Zug 2026 endgültig abfährt!

Dieses exklusive PDF ist nur für kurze Zeit gratis verfügbar.
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.